78 related articles for article (PubMed ID: 2573425)
1. Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2.
Eisenthal A; Rosenberg SA
Cancer Res; 1989 Dec; 49(24 Pt 1):6953-9. PubMed ID: 2573425
[TBL] [Abstract][Full Text] [Related]
2. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Eisenthal A; Cameron RB; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
4. The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha.
Eisenthal A; Rosenberg SA
J Immunol; 1989 Apr; 142(7):2307-13. PubMed ID: 2647849
[TBL] [Abstract][Full Text] [Related]
5. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
6. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
Hinuma S; Naruo K; Shiho O; Tsukamoto K
Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
[TBL] [Abstract][Full Text] [Related]
8. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
Berinstein N; Levy R
J Immunol; 1987 Aug; 139(3):971-6. PubMed ID: 3496394
[TBL] [Abstract][Full Text] [Related]
9. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
Munn DH; Cheung NK
Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
[TBL] [Abstract][Full Text] [Related]
11. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
12. Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2.
Berinstein N; Starnes CO; Levy R
J Immunol; 1988 Apr; 140(8):2839-45. PubMed ID: 3258621
[TBL] [Abstract][Full Text] [Related]
13. In vivo requirement for asialo GM1 and Thy1 positive leukocytes for antitumor effect of rIL-2 +/- rIFN-gamma.
Silagi S; Dutkowski R; Schaefer A
Anticancer Res; 1988; 8(6):1265-9. PubMed ID: 2905882
[TBL] [Abstract][Full Text] [Related]
14. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
[TBL] [Abstract][Full Text] [Related]
15. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo.
Gill I; Agah R; Hu E; Mazumder A
Cancer Res; 1989 Oct; 49(19):5377-9. PubMed ID: 2788499
[TBL] [Abstract][Full Text] [Related]
17. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
Yang JC; Mulé JJ; Rosenberg SA
J Immunol; 1986 Jul; 137(2):715-22. PubMed ID: 2873187
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of IL-2 induces lymphokine-activated killer (LAK) cells capable of killing macrophages in various tissues.
Kamitani T; Suzuki H; Yano S
Immunology; 1989 Dec; 68(4):520-5. PubMed ID: 2606510
[TBL] [Abstract][Full Text] [Related]
19. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.
Eisenthal A; Lafreniere R; Lefor AT; Rosenberg SA
Cancer Res; 1987 Jun; 47(11):2771-6. PubMed ID: 3494504
[TBL] [Abstract][Full Text] [Related]
20. The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation.
Ericson SG; Benoit NE; Mills LE; Fanger MW
Exp Hematol; 1994 Mar; 22(3):283-9. PubMed ID: 7509291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
